1. Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro Surveill. 2016; 21: 30319.
2. O'Neill J, 2016. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. Available at: http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf/. Accessed Oct 6, 2021.
3. Tsuzuki S, Matsunaga N, Yahara K, et al. National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2020; 26: 367-71.
4. Tsuzuki S, Matsunaga N, Yahara K, et al. Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: A population-level study, Japan, 2015-2018. Int J Infect Dis. 2021; 108: 119-24.
5. Kolár M, Urbánek K, Látal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents. 2001; 17: 357-63.
6. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004; 10: 514-7.
7. Abdallah M, Badawi M, Amirah MF, et al. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU. J Antimicrob Chemother. 2017; 72: 3187-90.
8. World Health Organization, 2015. Global Action Plan on Antimicrobial Resistance. Available at: https://www.who.int/publications/i/item/9789241509763/. Accessed Oct 6, 2021.
9. 国際的に脅威となる感染症対策関係閣僚会議 2016. 薬剤耐性(AMR)対策アクションプラン 2016-2020. Available at: https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000120769.pdf/. Accessed Oct 6, 2021.
10. Kusama Y, Tsuzuki S, Muraki Y, et al. The effects of Japan's National Action Plan on Antimicrobial Resistance on antimicrobial use. Int J Infect Dis. 2021;103:154-6.
11. AMR 臨床リファレンスセンター. サーベイランス. Available at: https://amrcrc.ncgm.go.jp/surveillance/index.html/. Accessed Jan 17, 2022.
12. Muraki Y, Yagi T, Tsuji Y, et al. Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009-2013). J Glob Antimicrob Resist. 2016; 7: 19-23.
13. Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018; 24: 414-21.
14. Kusama Y, Ishikane M, Tanaka C, et al. Regional Variation of Antimicrobial Use in Japan from 2013-2016, as Estimated by the Sales Data. Jpn J Infect Dis. 2019; 72: 326-9.
15. Yamasaki D, Tanabe M, Muraki Y, et al. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011-2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. Infection. 2018; 46: 207- 14.
16. Kusama Y, Ishikane M, Tanaka C, et al. Aminoglycoside inhalational therapy: a potential pitfall of antimicrobial stewardship in outpatient settings. JAC Antimicrob Resist. 2020; 2: dlaa004.
17. European Centre for Disease Prevention and Control. Data source overview of antimicrobial consumption. Available at: https://www.ecdc.europa.eu/en/antimicrobial-consumption/database/data-source-overview/. Accessed Oct 6, 2021.
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2021. Available at: https://www.whocc.no/atc_ddd_index/. Accessed Oct 6, 2021.
19. 感染症教育コンソーシアム 抗菌薬使⽤量集計マニュアル作成チーム. 抗菌薬 使 ⽤ 量 集 計 マ ニ ュ ア ル Ver 1.1. Available at: http://amr.ncgm.go.jp/pdf/koukin_manual.pdf/. Accessed Oct 6, 2021.
20. 総務省. e-Stat. https://www.e-stat.go.jp/. Available at: Accessed Jan 17, 2022.
21. 厚⽣労働省. 薬価基準収載品⽬リスト及び後発医薬品に関する情報について. https://www.mhlw.go.jp/topics/2021/04/tp20210401-01.html. Available at: Accessed Jan 17, 2022.
22. 厚⽣労働省. 電⼦レセプト請求の電⼦化普及状況等(平成 27 年 4 ⽉診療分)について. Available at: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000099015.html/. Accessed Oct 6, 2021.
23. Koizumi R, Kusama Y, Asai Y, Yoshiaki G, Muraki Y, Ohmagari N. Effects of the cefazolin shortage on the sales, cost, and appropriate use of other antimicrobials. BMC Health Serv Res. 2021; 21 :1118.
24. 薬剤耐性ワンヘルス動向調査検討会. 薬剤耐性ワンヘルス動向調査年次報告書 2020. Available at: https://www.mhlw.go.jp/content/10900000/000715546.pdf/. Accessed Oct 6, 2021.
25. Kusama Y, Ishikane M, Tanaka C, et al. What is the impact of the change in DDD of amoxicillin and amoxicillin combined with β-lactamase inhibitors on nationwide surveillance of antimicrobial use? J Antimicrob Chemother. 2019; 74: 3119-21.
26. Koizumi R, Kusama Y, Muraki Y, et al. Effect of population inflow and outflow between rural and urban areas on regional antimicrobial use surveillance. PLoS One. 2021; 16: e0248338.
27. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14:1722-30.
28. Peñalva G, Högberg LD, Weist K, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24:1900656.
29. Batista AD, A Rodrigues D, Figueiras A, et al. Antibiotic Dispensation without a Prescription Worldwide: A Systematic Review. Antibiotics (Basel). 2020; 9: 786.
30. Sakeena MHF, Bennett AA, McLachlan AJ. Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: a systematic review. Int J Antimicrob Agents. 2018; 52: 771-782.